Skip to main content
SpringerLink
Log in

Adherence to warfarin treatment among patients with atrial fibrillation

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Background

Treatment with warfarin greatly reduces the risk of stroke related to atrial fibrillation, but will not be effective unless patients adhere to treatment. Lack of fixed dosing makes it difficult to objectively estimate adherence to treatment from prescription data.

Objective

To evaluate two methods that assess adherence to warfarin from prescription data.

Design

Retrospective study of Swedish health care registers.

Patients and methods

Age- and sex-specific dose requirements were determined from approx. 1 million blood tests and dosing instructions. By applying these dosages to 163,785 warfarin-treated patients with atrial fibrillation, we calculated the quantity of warfarin that was needed to keep these patients on effective treatment during a mean follow-up of 3.9 years and compared that with the dispensed quantities. The ratio of available drug/time at risk constitutes a measure of adherence on group level. In addition, time intervals between refills were used to assess discontinuation.

Results

Both methods showed that 45 % of the patients did not have enough warfarin to last 80 % of the time at risk. Between 16 and 21 % of the patients discontinued within the first year, followed by 8–9 % annually during the following years. Patients with high bleeding risk and patients with low embolic risk showed lower endurance.

Conclusions

Adherence to treatment with warfarin can be estimated on group level from prescription data and may be useful for comparison of adherence with warfarin and new oral anticoagulants. When applied to a large warfarin-treated cohort with atrial fibrillation, we found that adherence is low and that measures aiming for improvements are needed .

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Reference

  1. Camm AJ, Lip GY, De Caterina R et al (2012) 2012 focused update of the esc guidelines for the management of atrial fibrillation: An update of the 2010 esc guidelines for the management of atrial fibrillation developed with the special contribution of the european heart rhythm association. Europace 14:1385–1413

    Article  PubMed  Google Scholar 

  2. Aguilar MI, Hart R (2005) Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 3:CD001927

    PubMed  Google Scholar 

  3. Rosendaal FR, Cannegieter SC, van der Meer FJ et al (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236–239

    CAS  PubMed  Google Scholar 

  4. Connolly SJ, Pogue J, Eikelboom J et al (2008) Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118:2029–2037

    Article  CAS  PubMed  Google Scholar 

  5. Morgan CL, McEwan P, Tukiendorf A et al (2009) Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 124:37–41

    Article  CAS  PubMed  Google Scholar 

  6. Wallentin L, Yusuf S, Ezekowitz MD et al (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376:975–983

    Article  CAS  PubMed  Google Scholar 

  7. Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Eng J Med 365:883–891

    Article  CAS  PubMed  Google Scholar 

  8. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. New Eng J Med 361:1139–1151

    Article  CAS  PubMed  Google Scholar 

  9. Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. New Eng J Med 365:981–992

    Article  CAS  PubMed  Google Scholar 

  10. Jorgensen AL, Hughes DA, Hanson A et al (2013) Adherence and variability in warfarin dose requirements: assessment in a prospective cohort. Pharmacogenomics 14:151–163

    Article  CAS  PubMed  Google Scholar 

  11. Sappok T, Faulstich A, Stuckert E et al (2001) Compliance with secondary prevention of ischemic stroke: a prospective evaluation. Stroke 32:1884–1889

    Article  CAS  PubMed  Google Scholar 

  12. Hamann GF, Weimar C, Glahn J et al (2003) Adherence to secondary stroke prevention strategies–results from the german stroke data bank. Cerebrovasc Dis 15:282–288

    Article  PubMed  Google Scholar 

  13. De Schryver EL, van Gijn J, Kappelle LJ et al (2005) Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol 252:1316–1321

    Article  PubMed  Google Scholar 

  14. Gomes T, Mamdani MM, Holbrook AM et al (2012) Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med 172:1687–1689

    Article  PubMed  Google Scholar 

  15. Maxwell W, Bennett CL (2012) Will newer anticoagulants improve therapy persistence? Arch Intern Med 172:1689–1690

    Article  PubMed  Google Scholar 

  16. Wang Y, Kong MC, Ko Y (2013) Comparison of three medication adherence measures in patients taking warfarin. J Thromb Thrombol 36:416–421

    Article  CAS  Google Scholar 

  17. Auricula. In: Auricula annual report 2011 [auricula årsrapport 2011]. UCR, Uppsala Clinical Research Center 2013, http://www.ucr.uu.se/auricula/index.php/arsrapporter. Accessed 23 Jan 2014

  18. Mattson ME, Friedman LM (1984) Issues in medication adherence assessment in clinical trials of the national heart, lung, and blood institute. Controll Clin Trial 5:488–496

    Article  CAS  Google Scholar 

  19. Kimmel SE, Chen Z, Price M et al (2007) The influence of patient adherence on anticoagulation control with warfarin: results from the international normalized ratio adherence and genetics (in-range) study. Arch Intern Med 167:229–235

    Article  CAS  PubMed  Google Scholar 

  20. Yeaw J, Benner JS, Walt JG et al (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728–740

    PubMed  Google Scholar 

  21. Ewen S, Rettig-Ewen V, Mahfoud F et al (2014) Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol 103:173–182

    Article  CAS  PubMed  Google Scholar 

  22. Hylek EM, Evans-Molina C, Shea C et al (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115:2689–2696

    Article  CAS  PubMed  Google Scholar 

  23. Glader EL, Sjölander M, Eriksson M et al (2010) Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 41:397–401

    Article  PubMed  Google Scholar 

  24. White HD, Gruber M, Feyzi J et al (2007) Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 167:239–245

    Article  CAS  PubMed  Google Scholar 

  25. Nieuwlaat R, Connolly BJ, Hubers LM, ACTIVE Investigators et al (2012) Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. Thromb Res 129:715–719

    Article  CAS  PubMed  Google Scholar 

  26. Casciano JP, Dotiwala ZJ, Martin BC et al (2013) The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm 19:302–316

    PubMed  Google Scholar 

Download references

Conflict of interest

None of the authors have support from any company for the submitted work. MS has nothing to declare. LF has given lectures, received funding or participated as consultant to Sanofi-Aventis, Boehringer-Ingelheim, Bayer, BMS, and St Jude Medical.

Author information

Authors and Affiliations

  1. Clinical Pharmacology Unit, Department of Medicine/Solna, Karolinska Institute, Stockholm, Sweden

    Mika Skeppholm

  2. Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden

    Leif Friberg

  3. Department of Cardiology at Danderyd Hospital, Stockholm, Sweden

    Mika Skeppholm & Leif Friberg

Authors
  1. Mika Skeppholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leif Friberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mika Skeppholm.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplemental Table 1 Characteristics of patients in the cohorts (DOCX 14 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Skeppholm, M., Friberg, L. Adherence to warfarin treatment among patients with atrial fibrillation. Clin Res Cardiol 103, 998–1005 (2014). https://doi.org/10.1007/s00392-014-0742-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-014-0742-y

Keywords

Search

Navigation